Where Outsourced Programs Actually Go Wrong

In a post-mortem analysis of delayed pharmaceutical development programs, the root cause is rarely technical. It is almost always communication. The formulation team changed the API particle size specification but did not formally notify the manufacturing team. The client expected a stability report in a format that the CDMO was not using. A critical experiment was delayed because no one flagged the resource conflict two weeks in advance.

None of these are scientific failures. They are project management failures, and they are extraordinarily common in pharma outsourcing relationships.

What Good Project Management Looks Like in CDMO Partnerships

A Single Named Point of Contact

The most important feature of a well-managed CDMO partnership is having one person who owns the program. Not a team. Not a department. One named project manager who attends every meeting, tracks every deliverable, and is accountable to the client for the health of the program. When issues arise, you know exactly who to call, and that person knows exactly what is happening across every workstream.

Structured Reporting Cadence

Regular progress reports, written to a consistent template, give clients a clear view of what has been completed, what is in progress, and what is at risk. The best CDMOs produce reports that are informative regardless of whether everything is on track, because they flag emerging issues before they become urgent.

Proactive Risk Escalation

A CDMO project manager who only tells you about problems when they have already happened is not managing risk, they are reporting it. Proactive risk management means identifying the issues that could arise two to four weeks ahead and communicating them to the client in time for mitigation decisions to be made.

Common Failure Modes in CDMO Communication

How Ardena’s Project Management Model Works

Every Ardena program is assigned a dedicated project manager from kick-off through to delivery. That person is responsible for coordinating work across Ardena’s scientific teams, maintaining the program timeline, and communicating progress to the client on an agreed schedule.

Ardena operates a formal change control system that ensures any modification to scope, timeline, or specification is documented and agreed before implementation. Program status meetings are structured around a consistent agenda, and risk items are flagged in writing rather than raised informally in calls.For complex multi-site programs, the project manager acts as the interface between Ardena’s facilities, ensuring that work in Ghent, Oss, Assen, and Pamplona is coordinated and progresses in alignment with the overall program plan.

Why CDMO Selection Deserves More Due Diligence Than It Usually Gets

Choosing a contract development and manufacturing partner for a Phase I program is one of the most consequential decisions an early-stage drug developer makes. It shapes your timelines, your CMC package, and your ability to respond when something unexpected happens. Yet many biotech companies spend more time evaluating clinical CROs than they spend evaluating their CDMO.

This checklist covers the questions that experienced drug developers ask when evaluating a CDMO for first-in-human manufacturing. It is not exhaustive, but it addresses the areas where gaps most often lead to problems.

Phase I CDMO Evaluation Checklist

The Questions Most People Forget to Ask

What Happens When the Project Manager Leaves?

In a small CDMO, the quality of your experience often depends on one or two key people. It is worth asking directly what the continuity plan is if your primary contact leaves the organization during your program. An organization with robust knowledge management systems will have a clear answer.

How Does the CDMO Handle Competing Priorities?

CDMOs work with multiple clients simultaneously. When your program and a higher-priority client need the same piece of equipment or the same specialist at the same time, something has to give. Ask how the CDMO manages competing priorities and what commitments it makes regarding dedicated capacity.

What Does ‘We Can Do That’ Actually Mean?

Some CDMOs have broad service lists but narrow actual capabilities. If a service is listed but has only been performed once or twice, the learning curve comes at your expense. Ask for the number of programs completed using the specific technology relevant to your molecule.

How Ardena Approaches Phase I Partnerships

Ardena’s Phase I manufacturing capabilities span oral solids, complex injectables, and nanomedicines across its European network. Each program is managed by a dedicated project manager and supported by a scientific team that has been involved from early development. The CMC regulatory function is integrated, so the team producing your GMP batches is aligned with the team writing your IND or IMPD CMC section.

The Cheapest Quote Is Not Always the Cheapest Program

When a biotech company evaluates its outsourcing options, the instinct is often to find the best vendor for each individual piece of work. The best formulation house for development, the best API lab for synthesis, the best analytical CRO for method validation, and the best CMO for GMP manufacture. On paper, combining specialists seems logical. In practice, it generates a category of cost that almost never appears in the project budget: coordination overhead.

This article looks at the real cost of managing multiple vendors across a pharmaceutical development program, and why an increasing number of drug developers are consolidating with integrated partners to reduce it.

The Management Tax

Every vendor in your program needs a relationship owner. Someone on your team who attends the technical meetings, reviews the reports, chases the timelines, and translates between the scientific language used by each organization. If your program involves four vendors, you need four of those relationships running in parallel, each generating governance overhead.

For a small biotech with a lean team, that overhead is disproportionately expensive. A program director spending 40% of their time on vendor coordination is not spending 40% of their time on the science. That is a real cost, even if it does not appear on any invoice.

Where Multi-Vendor Costs Actually Show Up

The Quality Risk That Is Harder to Quantify

Beyond the time costs, multi-vendor programs carry a qualitative risk that is difficult to put a number on. When something goes wrong in a development program, and in early-stage development something almost always does, the first question is which vendor is responsible. That question becomes harder to answer when multiple organizations have touched the molecule at different stages, and the answer shapes who bears the cost of fixing it.

The ICH Q10 pharmaceutical quality system framework emphasizes the importance of clear knowledge ownership throughout the product lifecycle. Multi-vendor models create structural ambiguity around that ownership, particularly at the interfaces between organizations.

What Consolidation Looks Like with Ardena

Ardena’s multi-site network is designed to serve as a single development and manufacturing partner for the full pre-clinical to clinical journey. Drug substance work, formulation development, analytical services, and GMP manufacturing operate within the same quality system and project management framework. For a program that might otherwise involve three or four separate vendors, consolidating with Ardena means one quality agreement, one project manager, one reporting cadence, and one organization accountable for the outcome.

The Hidden Cost That Nobody Puts in the Budget

When a drug development team builds a plan for getting from lead candidate to Phase I, they typically account for formulation development costs, GMP manufacturing costs, analytical work, and regulatory fees. What rarely appears on the spreadsheet is the cost of moving data and processes between vendors.

Technology transfer, the act of handing a process from one organization to another so that it can be reproduced under GMP conditions, is one of the most reliable sources of delay in pharmaceutical development. It is rarely catastrophic on its own, but it consistently adds weeks and months that were not planned for, and the friction compounds across every handoff.

What Actually Goes Wrong in a Tech Transfer

Documentation Gaps

A formulation scientist who developed a process knows things that are not written down. They know which step needs careful attention, which parameter drifts if the ambient temperature changes, and what the analytical method looked like in its early iterations. When that knowledge has to be formalized and transmitted to a new team at a different organization, some of it is always lost.

Analytical Method Inconsistencies

Drug substance and drug product often use overlapping analytical methods, but those methods may have been developed by different teams working in different labs with different equipment. Reconciling them at the point of tech transfer can take weeks, particularly if one set of methods was designed for a research context and needs to be translated into a GMP-validated form.

Communication Overhead

Every time there is an unexpected result during tech transfer, a question needs to go back to the originating organization, get answered by someone who may no longer be the primary contact for that program, and be interpreted by a new team. That loop takes time. ICH Q10 on pharmaceutical quality systems acknowledges the importance of knowledge management precisely because of how often valuable process understanding is lost at organizational boundaries.

The Integrated Model: What It Means in Practice

An integrated CDMO is one where drug substance development, drug product formulation, analytical services, and GMP manufacturing sit within the same organization, connected by shared systems, shared data, and shared project management. The scientist who identifies the optimal crystalline form in pre-formulation is connected to the team that formulates the drug product, which is connected to the team that executes the GMP campaign.

The transfer is not eliminated. It is replaced by a conversation.

Timeline Comparison

The timeline figures above represent typical ranges based on industry experience with multi-vendor and integrated outsourcing models. Actual timelines depend on the complexity of the program and the quality of the originating technical package.

How Ardena’s Multi-Site Model Delivers Integration

Ardena’s facilities are not independent sites operating under a shared brand. They are connected nodes in a single development and manufacturing network. The solid-state research team in Ghent feeds its polymorph and salt screening data directly into the drug product formulation work. The analytical team in Assen uses methods that are coordinated with the analytical groups in other sites from the start of a program.

When a project moves from preclinical development into GMP manufacturing, the same project manager who has been running the program continues to own it. There is no formal handover between a development team and a manufacturing team, because they are part of the same organization.This is what Ardena means when it describes a ‘molecule to patient’ approach. It is not a marketing phrase. It is a structural commitment to keeping the people who understand your molecule involved throughout its development. See our related article on what to look for when selecting a Phase I CDMO for a practical checklist of questions to ask potential partners about their integration model.